Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renaud Felten

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Autoimmunity Reviews|December 21, 2023
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness studyVirginia Solitano, Paola Facheris, Magnus Petersen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 21, 2022
Variability of Primary Sjögren's Syndrome Is Driven by Interferon-α and Interferon-α Blood Levels Are Associated With the Class II HLA-DQ LocusDiana Trutschel, Pierre Bost, Xavier Mariette, et al.
RMD Open|March 15, 2024
Concordance and agreement between different activity scores in polymyalgia rheumaticaJustine D'Agostino, Aghiles Souki, Anne Lohse, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2025
Maintenance of remission after tocilizumab withdrawal in patients with glucocorticoid-dependent polymyalgia rheumaticaBaptiste Chevet, Aghiles Souki, Emmanuel Nowak, et al.
Joint Bone Spine|April 7, 2024
Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumaticaDaniel Wendling, Omar Al Tabaa, Baptiste Chevet, et al.
Rheumatology (Oxford, England)|November 3, 2021
New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL studyJean-Guillaume Letarouilly, Thao Pham, Adeline Pierache, et al.
Annals of the Rheumatic Diseases|November 19, 2020
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trialRenaud Felten, Valérie Devauchelle-Pensec, Raphaèle Seror, et al.
RMD Open|November 1, 2022
Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)Jacques-Eric Gottenberg, Aurore Chaudier, Yves Allenbach, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Autoimmunity Reviews|December 21, 2023
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness studyVirginia Solitano, Paola Facheris, Magnus Petersen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 21, 2022
Variability of Primary Sjögren's Syndrome Is Driven by Interferon-α and Interferon-α Blood Levels Are Associated With the Class II HLA-DQ LocusDiana Trutschel, Pierre Bost, Xavier Mariette, et al.
RMD Open|March 15, 2024
Concordance and agreement between different activity scores in polymyalgia rheumaticaJustine D'Agostino, Aghiles Souki, Anne Lohse, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2025
Maintenance of remission after tocilizumab withdrawal in patients with glucocorticoid-dependent polymyalgia rheumaticaBaptiste Chevet, Aghiles Souki, Emmanuel Nowak, et al.
Joint Bone Spine|April 7, 2024
Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumaticaDaniel Wendling, Omar Al Tabaa, Baptiste Chevet, et al.
Rheumatology (Oxford, England)|November 3, 2021
New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL studyJean-Guillaume Letarouilly, Thao Pham, Adeline Pierache, et al.
Annals of the Rheumatic Diseases|November 19, 2020
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trialRenaud Felten, Valérie Devauchelle-Pensec, Raphaèle Seror, et al.
RMD Open|November 1, 2022
Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)Jacques-Eric Gottenberg, Aurore Chaudier, Yves Allenbach, et al.
Pageof 7